Back to Authors

Goldberg, Terry E.

https://orcid.org/0000-0002-2455-7247

Mayo Clinic

Division of Geriatric Psychiatry New York NY USA

Citations 2

Measuring cognition and function in the preclinical stage of Alzheimer's disease
Weıntraub, Sandra , Farias, Sarah Tomaszewski , Goldberg, Terry E. , Hendrix, James A. , Jaeger, Judith , Park, Denise C. , Ropacki, Michael T., Sikkes, Sietske A.M. , Bain, Lisa J. , Brashear, Robert, Budur, Kumar, Graf, Ana, Martényi, Ferenc, Storck, Marta Segardahl, Randolph, Christopher , Carrillo, María C. , Knopman, David S. , Langbaum, Jessica B. S. , Welsh-Bohmer, Kathleen Anne

Alzheimer's & Dementia: Translational Research & Clinical Interventions | February 13, 2018 | Volume: 4 | Issue: 1 | Pages: 64-75

10.1016/j.trci.2018.01.003 Get It

Abstract The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.
MR spectroscopy, APOE genotype, and evolving β-amyloid pathology
Kantarci, Kejal , Goldberg, Terry E. , Kantarci, Kejal

Neurology | April 16, 2016 | Volume: 86 | Issue: 19 | Pages: 1750-1751

10.1212/wnl.0000000000002680 Get It